Clinical Oncology UpdateEtoposide: four decades of development of a topoisomerase II inhibitor
Introduction
DNAtopoisomerases are nuclear enzymes which make transient DNA strand breaks allowing the cell to manipulate the topology of its DNA1, 2. DNA topoisomerases are essential for DNA replication, transcription, chromosomal segregation and DNA recombination. Two major topoisomerase forms are present in all cells: the type I enzyme which makes single-strand cuts in DNA and type II enzymes which cut and pass double-stranded DNA. DNA topoisomerase I was first described in 1971[3]and DNA topoisomerase II in 1976[4]. Several commercially available antineoplastic drugs are now known to be inhibitors of topoisomerase I (irinotecan, topotecan) or topoisomerase II (etoposide, teniposide, doxorubicin, daunorubicin, idarubicin, mitoxantrone). This review will concentrate primarily on the development of etoposide as an antineoplastic agent. Etoposide was the first agent recognised as a topoisomerase II inhibiting anticancer drug. Research on etoposide has helped the understanding of mechanisms by which drugs poison topoisomerase II. Recognition of the relationship of topoisomerase II inhibition and a resulting antineoplastic effect has stimulated development of other agents. Currently available topoisomerase II inhibitors are briefly described.
Section snippets
Historical development
Podophyllotoxins have been used as medications by various cultures for over 1,000 years (Table 1)[5]. In the 19th century, podophyllin was found to be topically effective for skin cancers. In 1946, the antimitotic properties of podophyllin were established[6]. Clinical evaluation of podophyllotoxin and selected derivatives demonstrated modest antineoplastic activity. However, toxicity of podophyllin was prohibitive7, 8. In the 1950s, investigators at Sandoz Pharmaceuticals began synthesising a
Other topoisomerase II targeting antineoplastic agents
In addition to etoposide, five other topoisomerase II targeting antineoplastic agents (teniposide, doxorubicin, daunorubicin, idarubicin and mitoxantrone) have been approved for clinical use in the US by the Food and Drug Administration (Table 8). Other topoisomerase II inhibitors (Table 9) which have demonstrated antitumour activity in animal or clinical studies have not been approved for general clinical use in the US.
Conclusion
Four decades of research have led to the recognition that certain antineoplastic drugs poison topoisomerase II, thereby killing cancer cells. These studies have provided a new target site for drug development. Etoposide, the lead drug in this class, continues to be a widely used agent with activity against a wide range of cancers. It is a standard component of therapy for small cell lung cancer, testicular cancers and lymphomas. Optimal and convenient schedules have been devised over the past
References (72)
- et al.
Topoisomerase poisons: harnessing the dark side of enzyme mechanisms
J Biol Chem
(1995) - et al.
VP-16-214 (Etoposide). The mandrake root from Issyk-Kul
Am J Med
(1982) Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small cell lung cancer: a stopped multicenter randomized trial
Lancet
(1996)Adriamycin-dependent release of iron from microsomal membranes
Arch Biochem Biophys
(1989)- et al.
DNA Topoisomerases: essential enzymes and lethal targets
Ann Rev Pharmacol Toxicol
(1994) Interaction between DNA and E. coli: protein omega
J Mol Biol
(1971)- et al.
An enzyme that introduces superhelical turns into DNA
Proc Natl Acad Sci USA
(1976) The clinical pharmacology of etoposide
Cancer
(1991)- et al.
The similarity of the effect of podophyllotoxin and colchicine and their use in the treatment of condylomata acuminata
Science
(1946) - et al.
Effect of alpha-peltatin, beta-peltatin and podophyllotoxin on lymphoma and other transplanted tumors
J Natl Cancer Inst
(1950)
The chemical and biological route from podophyllotoxin glucoside to etoposide: Ninth Cain Memorial Award Lecture
Cancer Res
Current status of etoposide in the management of small cell lung cancer
Cancer
Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin’s lymphomas and other malignancies
Cancer Treat Rep
Etoposide: current and future status
Cancer
New chemotherapies for ovarian cancer
Cancer
Current strategies in the management of locoregional and metastatic gastric carcinoma
Cancer
Etoposide in the management of metastatic breast cancer
Cancer
Etoposide: an update
Clin Pharmacy
Effect of podophyllotoxin and VP-16 on microtubule assembly in vitro and nucleoside transport in HeLa cells
Biochemistry
DNA damage as a basis for 4-demethylepipodophyllotoxicity
Cancer Res
Cracking of ABS plastic devices used to infuse undiluted etoposide injection
Am J Hosp Pharm
EPEG, a new antineoplastic epipodophyllotoxin
Clin Pharmacol Ther
Etoposide pharmacology
Semin Oncol
PTG, a new antineoplastic epipodophyllotoxin
Clin Pharmacol Ther
Predicting etoposide toxicity: relationship to organ function and protein binding
J Clin Oncol
Pharmacodynamic modeling of prolonged administration of etoposide
Cancer Chemother Pharmacol
Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer
Clin Cancer Res
Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213
Cancer Treat Rep
Cited by (829)
A review on non-small cell lung cancer
2024, VacunasStrategic application of CuAAC click chemistry in the modification of natural products for anticancer activity
2023, European Journal of Medicinal Chemistry ReportsFerrocene/ β-cyclodextrin based supramolecular nanogels as theranostic systems
2023, Biomedicine and Pharmacotherapy